Go Pro
→ 'How Much Can I Actually Spend Each Year With $2.5M Saved?' (From SmartAsset) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
$5.84
+1.3%		$4.76
$3.31
▼
$6.18
$758.45M1.181.04 million shs324,485 shs
CryoPort, Inc. stock logo
CYRX
CryoPort
$17.50
+1.0%		$15.96
$7.61
▼
$17.98
$886.12M1.89585,144 shs122,600 shs
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
$13.36
+11.7%		$7.78
$5.37
▼
$17.58
$897.84M1.761.24 million shs1.92 million shs
Simulations Plus, Inc. stock logo
SLP
Simulations Plus
$18.48
0.0%		$18.38
$11.09
▼
$21.01
$373.75M1.33352,264 shs147,668 shs
10 Best Stocks to Own in Fall 2026 Cover
10 Best Stocks to Own in Fall 2026

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
+0.35%+0.88%+23.08%+25.76%+70.41%
CryoPort, Inc. stock logo
CYRX
CryoPort
-0.35%-1.42%+7.64%+9.21%+84.06%
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
+13.78%+27.24%+71.52%+16.63%-9.30%
Simulations Plus, Inc. stock logo
SLP
Simulations Plus
0.00%+0.38%+0.49%+0.71%+24.03%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
$5.84
+1.3%		$4.76
$3.31
▼
$6.18
$758.45M1.181.04 million shs324,485 shs
CryoPort, Inc. stock logo
CYRX
CryoPort
$17.50
+1.0%		$15.96
$7.61
▼
$17.98
$886.12M1.89585,144 shs122,600 shs
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
$13.36
+11.7%		$7.78
$5.37
▼
$17.58
$897.84M1.761.24 million shs1.92 million shs
Simulations Plus, Inc. stock logo
SLP
Simulations Plus
$18.48
0.0%		$18.38
$11.09
▼
$21.01
$373.75M1.33352,264 shs147,668 shs
10 Best Stocks to Own in Fall 2026 Cover
10 Best Stocks to Own in Fall 2026

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
+0.35%+0.88%+23.08%+25.76%+70.41%
CryoPort, Inc. stock logo
CYRX
CryoPort
-0.35%-1.42%+7.64%+9.21%+84.06%
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
+13.78%+27.24%+71.52%+16.63%-9.30%
Simulations Plus, Inc. stock logo
SLP
Simulations Plus
0.00%+0.38%+0.49%+0.71%+24.03%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
2.33
Hold$5.56-4.67% Downside
CryoPort, Inc. stock logo
CYRX
CryoPort
2.67
Moderate Buy$18.002.88% Upside
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
1.50
Reduce$6.33-52.58% Downside
Simulations Plus, Inc. stock logo
SLP
Simulations Plus
1.88
Reduce$17.25-6.63% Downside

Current Analyst Ratings Breakdown

Latest SLP, CYRX, DNA, and CTKB Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/21/2026
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
9/18/2026
CryoPort, Inc. stock logo
CYRX
CryoPort
BTIG Research logo
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$25.00
9/9/2026
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
Oppenheimer Holdings, Inc. logo
Oppenheimer
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$5.00
9/4/2026
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
BTIG Research logo
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell$5.00
8/17/2026
CryoPort, Inc. stock logo
CYRX
CryoPort
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHold (C-) ➝ Sell (D)
8/17/2026
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold
8/7/2026
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$5.00
8/7/2026
CryoPort, Inc. stock logo
CYRX
CryoPort
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$12.00 ➝ $16.00
8/7/2026
CryoPort, Inc. stock logo
CYRX
CryoPort
Roth Capital logo
Roth Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$21.00
8/7/2026
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuy ➝ Hold$12.00 ➝ $9.00
8/7/2026
CryoPort, Inc. stock logo
CYRX
CryoPort
Needham & Company LLC logo
Needham & Company LLC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$15.00 ➝ $19.00
(Data available from 9/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
$206.71M3.67N/AN/A$2.67 per share2.19
CryoPort, Inc. stock logo
CYRX
CryoPort
$176.18M5.03N/AN/A$9.19 per share1.90
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
$132.42M6.79N/AN/A$8.74 per share1.53
Simulations Plus, Inc. stock logo
SLP
Simulations Plus
$79.18M4.72$1.43 per share12.91$6.20 per share2.98
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
-$66.54M-$0.62N/AN/AN/A-38.98%-12.40%-9.17%11/4/2026 (Estimated)
CryoPort, Inc. stock logo
CYRX
CryoPort
$78.30M-$0.90N/AN/AN/A-20.05%-7.20%-4.30%11/3/2026 (Estimated)
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
-$312.76M-$5.01N/AN/AN/A-259.96%-60.27%-26.88%11/5/2026 (Estimated)
Simulations Plus, Inc. stock logo
SLP
Simulations Plus
-$64.72M$0.4046.19N/AN/A9.88%13.50%12.45%10/29/2026 (Estimated)

Latest SLP, CYRX, DNA, and CTKB Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2026Q2 2026
CryoPort, Inc. stock logo
CYRX
CryoPort
-$0.1933-$0.20-$0.0067-$0.20$48.18 million$48.97 million
8/5/2026Q2 2026
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
-$0.0933-$0.09+$0.0033-$0.09$47.31 million$48.14 million
8/5/2026Q2 2026
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
-$0.8950-$0.75+$0.1450-$0.75$24.05 million$20.16 million
7/9/2026Q3 2026
Simulations Plus, Inc. stock logo
SLP
Simulations Plus
$0.2325$0.30+$0.0675$0.18$20.90 million$21.89 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
N/AN/AN/AN/AN/A
CryoPort, Inc. stock logo
CYRX
CryoPort
N/AN/AN/AN/AN/A
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
N/AN/AN/AN/AN/A
Simulations Plus, Inc. stock logo
SLP
Simulations Plus
N/AN/A-100.00%N/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
N/A
4.48
3.86
CryoPort, Inc. stock logo
CYRX
CryoPort
N/A
2.08
1.98
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
N/A
4.57
4.57
Simulations Plus, Inc. stock logo
SLP
Simulations Plus
N/A
5.54
5.54

Institutional Ownership

CompanyInstitutional Ownership
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
69.46%
CryoPort, Inc. stock logo
CYRX
CryoPort
92.90%
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
78.63%
Simulations Plus, Inc. stock logo
SLP
Simulations Plus
78.08%

Insider Ownership

CompanyInsider Ownership
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
10.36%
CryoPort, Inc. stock logo
CYRX
CryoPort
9.50%
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
12.69%
Simulations Plus, Inc. stock logo
SLP
Simulations Plus
19.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
702129.98 million116.52 millionOptionable
CryoPort, Inc. stock logo
CYRX
CryoPort
73850.65 million45.84 millionOptionable
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
48567.34 million58.80 millionOptionable
Simulations Plus, Inc. stock logo
SLP
Simulations Plus
21320.23 million16.36 millionOptionable

Recent News About These Companies

Simulations Plus, Inc. (NASDAQ:SLP) Stock Has Average Price Target of $17.25
September 25, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31047178
Simulations Plus, Inc. (NASDAQ:SLP) Receives Average Rating of "Reduce" from Analysts
September 25, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-simulations-plus-inc-nasdaq-slp-receives-average-rating-of-reduce-from-analysts-2026-09-25/
Simulations Plus (NASDAQ:SLP) Stock Crosses Above 200-Day Moving Average – Here’s What Happened
September 24, 2026  |  defenseworld.netD
Simulations Plus (NASDAQ:SLP) Stock Crosses Above 200-Day Moving Average - Here's What Happened
September 24, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-simulations-plus-nasdaq-slp-stock-crosses-above-200-day-moving-average-heres-what-happened-2026-09-24/
Critical Analysis: Maravai LifeSciences (NASDAQ:MRVI) vs. Simulations Plus (NASDAQ:SLP)
September 22, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31039318
Simulations Plus Says FDA's Cosmetics Branch Adopts ADMET Predictor
September 18, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/technology/ai/articles/simulations-plus-says-fda-apos-084325040.html
Simulations Plus Expands FDA Adoption of ADMET Predictor® with New Licenses for the Cosmetics Regulatory Science Branch
September 17, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260917938732/en/Simulations-Plus-Expands-FDA-Adoption-of-ADMET-Predictor%C2%AE-with-New-Licenses-for-the-Cosmetics-Regulatory-Science-Branch/
Squarepoint Ops LLC Sells 58,282 Shares of Simulations Plus, Inc. $SLP
September 16, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-squarepoint-ops-llc-sells-58282-shares-of-simulations-plus-inc-slp-2026-09-16/
Johnson Fistel Investigates Simulations Plus Following Revenue Guidance Cut and Accounting Disclosures
September 15, 2026  |  newsfilecorp.comN
Johnson Fistel Investigates Simulations Plus Following Revenue Guidance Cut and Accounting Disclosures
September 10, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/10/3359750/0/en/johnson-fistel-investigates-simulations-plus-following-revenue-guidance-cut-and-accounting-disclosures.html
First Light Asset Management LLC Raises Position in Simulations Plus, Inc. $SLP
September 10, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-first-light-asset-management-llc-raises-position-in-simulations-plus-inc-slp-2026-09-10/
Bank of New York Mellon Corp Takes $1.25 Million Position in Simulations Plus, Inc. $SLP
September 10, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-bank-of-new-york-mellon-corp-takes-125-million-position-in-simulations-plus-inc-slp-2026-09-10/
Groupe la Francaise Acquires Shares of 127,200 Simulations Plus, Inc. $SLP
September 8, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-groupe-la-francaise-acquires-shares-of-127200-simulations-plus-inc-slp-2026-09-08/
BlackRock Inc. Makes New Investment in Simulations Plus, Inc. $SLP
September 3, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-blackrock-inc-makes-new-investment-in-simulations-plus-inc-slp-2026-09-03/
Simulations Plus, Inc. (NASDAQ:SLP) Given Consensus Recommendation of "Reduce" by Analysts
August 31, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-simulations-plus-inc-nasdaq-slp-given-consensus-recommendation-of-reduce-by-analysts-2026-08-31/
Johnson Fistel Investigates Simulations Plus Following Revenue Guidance Cut and Accounting Disclosures
August 27, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/27/3352164/0/en/johnson-fistel-investigates-simulations-plus-following-revenue-guidance-cut-and-accounting-disclosures.html
Johnson Fistel Investigates Simulations Plus Following Revenue Guidance Cut and Accounting Disclosures
August 20, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/20/3348549/0/en/johnson-fistel-investigates-simulations-plus-following-revenue-guidance-cut-and-accounting-disclosures.html
Simulations Plus Announces Expiration of Hart-Scott-Rodino Waiting Period for Pending Acquisition by Altaris
August 13, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260813655754/en/Simulations-Plus-Announces-Expiration-of-Hart-Scott-Rodino-Waiting-Period-for-Pending-Acquisition-by-Altaris/
Johnson Fistel Investigates Simulations Plus Following Revenue Guidance Cut and Accounting Disclosures
August 6, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/06/3340484/0/en/johnson-fistel-investigates-simulations-plus-following-revenue-guidance-cut-and-accounting-disclosures.html
Simulations Plus Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Simulations Plus, Inc. - SLP
July 30, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260730539938/en/simulations-plus-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-simulations-plus-inc.---slp/
Simulation Plus, Inc. Securities Fraud Investigation - Robbins LLP is Investigating Investor Losses in SLP Due to Possible Violations of Securities Laws
July 29, 2026  |  newsfilecorp.comN

New MarketBeat Followers Over Time

Media Sentiment Over Time

Cytek Biosciences stock logo

Cytek Biosciences NASDAQ:CTKB

$5.83 +0.07 (+1.18%)
As of 01:02 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. The company also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, an automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in European, Latin American, and the Middle Eastern countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.

CryoPort stock logo

CryoPort NASDAQ:CYRX

$17.50 +0.18 (+1.02%)
As of 01:02 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services. It also provides CRYOGENE, an unparalleled solution that offers pre-clinical temperature-controlled biological materials management services comprising specimen storage, processing, collection, and retrieval; CRYOPD, a temperature-controlled logistics solution, which include temperature-controlled packaging and transport solutions from cryogenic temperature to controlled ambient; and IntegriCell services that comprise apheresis/leukapheresis collection, Cryoshuttle transportation, cryo-process optimization and processing services. In addition, the company offers MVE Biological Solutions' Fusion cryogenic system, a self-sustaining cryogenic freezer; MVE Biological Solutions' Vario cryogenic system, a cryogenic freezer system that supports temperatures between -20°C and -150°C; Cryoport Cryoshuttle provides clients with dedicated local transportation support; and Tec4Med. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; and incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. Cryoport, Inc. was founded in 1999 and is headquartered in Brentwood, Tennessee.

Ginkgo Bioworks stock logo

Ginkgo Bioworks NYSE:DNA

$13.39 +1.43 (+11.97%)
As of 01:02 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Simulations Plus stock logo

Simulations Plus NASDAQ:SLP

$18.48 -0.01 (-0.03%)
As of 01:01 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. The company also provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, RENAsym, IPFsym, and MITOsym products. In addition, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Further, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Additionally, it offers creative and insightful consulting services to support its quantitative systems pharmacology/quantitative systems toxicology modelling. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas